

prior authorization (PA) checklist for VYEPTI® (eptinezumab-jjmr)

VYEPTI is the only IV calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraines in adults.¹

This checklist is for informational purposes only and can help organize information that may be required. It provides an overview of information which may be required for the patient's insurance. It does not guarantee reimbursement of coverage, and is not intended to be a substitute for, or to influence, the independent clinical decision of the prescriber.

Step 1 Insurance Investigation

To understand the PA requirements for each plan, offices must contact the insurance providers, as different plans may have different requirements

PA considerations vary between plans, including processes, step requirements, duration of approval, and other relevant information.

Step 2 Patient/Provider Information

Name:

Date of birth:

Insurance plan:

Specialist, or specialist consulted:

Provider ID number:

Initial Authorization Request Reauthorization Request (Complete the following items)

- Reauthorization criteria:
- Has the patient experienced a reduction in migraine: frequency, duration, and migraine free days due to therapy?

Some plans may require documents to support the PA, including a copy of your patient's chart notes.

Step 3 Diagnosis/Treatment Information

Diagnosis/ICD-10-CM:

Average number of migraine days
per month over the past 3 months:

Dose: 100 mg 300 mg Other

Symptoms

Headache days (per month):

Headache lasting (hrs):

Nausea/Vomiting Yes No

Photophobia/Phonophobia Yes No

Unilateral headache Yes No

Pulsating/Throbbing Yes No

Moderate/Severe pain Yes No

Aggravated by walking
stairs/Physical exercise Yes No

Other:

ICD-10-CM=International Classification of Diseases,
Tenth Revision, Clinical Modification; IV=intravenous.

- Note previous medication(s) tried and failed/discontinued (list the reason(s) for failure/discontinuation, including patient/drug combination failure):

Other Reason(s) for Failure/Discontinuation:

- Note all previous acute migraine medications taken by the patient within the last 3 months and any inadequate responses.
- Note all previous preventive medications taken by the patient, inadequate responses, and the duration of the trial period.
 - Plans may have a minimal trial period of preferred products in their coverage policies.

Some insurance plan requirements may classify migraine patients as episodic or chronic based on the number of headache and migraine days experienced in a month.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Please see the Important Safety Information on page 2. For more information, see the Full Prescribing Information and Patient Information or go to vyeptihcp.com.



Below are examples of the various preventive and acute drug classes. Please note that this is not a comprehensive list.

Preventive Examples

Antidepressants	Antiepileptics/ Anticonvulsants	Beta-blockers	Calcium Channel Blockers	Angiotensin-Converting Enzyme Inhibitors/ Angiotensin II Receptor Blockers	anti-CGRPs
Amitriptyline	Divalproex sodium	Atenolol	Diltiazem	Candesartan	Aimovig® (erenumab-aooe)
Citalopram	Gabapentin	Metoprolol	Nifedipine	Enalapril	Ajovy® (fremanezumab-vfrm)
Doxepin	Topiramate	Nadolol	Nimodipine	Irbesartan	Emgality® (galcanezumab-gnlm)
Fluoxetine	Valproic acid	Propranolol	Verapamil	Lisinopril	Nurtec ODT® (rimegepant)
Fluvoxamine		Timolol		Losartan	Qulipta™ (atogepant)
Mirtazapine				Olmesartan	Ubrelvy® (ubrogepant)
Nortriptyline				Ramipril	
Paroxetine				Valsartan	
Protriptyline					
Sertraline					
Venlafaxine					

Acute/Abortive Examples

NSAIDs/Analgesics	Ergot Alkaloid	Derivative Triptans	Combination/Other	anti-CGRPs
Acetaminophen	Ergotamine	Almotriptan	Acetaminophen/aspirin/ caffeine	Nurtec ODT
Aspirin	Dihydroergotamine	Eletriptan	Butalbital/acetaminophen/ caffeine	Ubrelvy
Diclofenac		Frovatriptan	Butalbital/aspirin/caffeine	
Ibuprofen		Naratriptan	Butorphanol	
Naproxen		Rizatriptan	Ergotamine/caffeine	
		Sumatriptan	Sumatriptan/naproxen	
		Zolmitriptan		

CGRP=calcitonin gene-related peptide; NSAIDs=non-steroidal anti-inflammatory drugs.

All trademarks are property of their respective owners.

INDICATION

VYEPTI® (eptinezumab-jjmr) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, see the Full [Prescribing Information](#) and [Patient Information](#) or go to vyeptihcp.com.

Reference: 1. VYEPTI [package insert]. Deerfield, IL. Lundbeck.



©2023 Lundbeck. All rights reserved. VYEPTI and VYEPTI CONNECT are trademarks of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-100513v4



For more information about VYEPTI CONNECT™ or to be connected with a Field Reimbursement Specialist, visit vyepticonnect.com, call 833-4-VYEPTI (833-489-3784), Option 1, or talk with a sales representative.